The United Laboratories International (HKG:3933) said Cefoperazone Sodium and Sulbactam Sodium for Injection passed China National Medical Products Administration's consistency evaluation, a Wednesday Hong Kong bourse filing said.
The drug was submitted by the Zhongshan Branch of Zhuhai United Laboratories, a unit of the firm.
The drug is a cephalosporin antibiotic which, when used as monotherapy, is indicated for the treatment of various infections, including respiratory tract infections, urinary tract infections, meningitis, and genital tract infections.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments